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background:  High on-treatment platelet reactivity is an independent risk factor of major adverse cardiovascular events following 
percutaneous coronary intervention or Acute Coronary Syndrome (ACS). HIV-infected patients have a higher risk of recurrent events after 
ACS than HIV uninfected patients. We hypothesized that this increased risk is driven by higher platelet reactivity.
methods:  In a case-control study, 80 HIV-infected patients and 160 HIV-uninfected patients with a first episode of ACS treated with 
percutaneous coronary intervention were matched for age, gender, diabetes mellitus and anti-platelet therapy. The primary end-point was 
the residual platelet reactivity (RPA) on dual antiplatelet therapy assessed by light transmission aggregometry (LTA, 20µM ADP).
Results:  Baseline characteristics were balanced between both groups except for a significant lower level of LDL cholesterol, creatinine 
clearance, body mass index and a significant higher level of triglycerides in HIV versus non-HIV patients. RPA was significantly higher in 
HIV versus non-HIV patients using LTA (23.85±2.7 vs.15.29±1.5 RPA, p=0.0004). Consistent findings were obtained using the VerifyNow-
P2Y12 point-of-care assay (132.3±10.3 vs.107.7±7.6 PRU for HIV and non-HIV, respectively, p=0.0065) and the Vasodilator Stimulated 
Phosphoprotein (VASP)-Platelet Reactivity Index (PRI) assay, dedicated to the monitoring of specific platelet ADP receptor (P2Y12) 
antagonists (45.2+/-2.6 vs.34.2+/-2.3, PRI for HIV and non-HIV, respectively, p=0.0006). Of interest, these differences were observed 
irrespective of the potency of the P2Y12 inhibitor and of exposure to protease inhibitor. This study was not designed for clinical outcome.
conclusion:  HIV-infected patients presenting with a first episode of ACS have higher platelet reactivity on dual antiplatelet therapy than 
non-HIV. This may account for the worse outcome of coronary artery disease in HIV patients.
